Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Legend Biotech (LEGN) over the last 6 years, with Dec 2024 value amounting to $277.6 million.

  • Legend Biotech's Total Current Liabilities rose 60.05% to $433.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $433.6 million, marking a year-over-year increase of 60.05%. This contributed to the annual value of $277.6 million for FY2024, which is 28.29% up from last year.
  • Legend Biotech's Total Current Liabilities amounted to $277.6 million in FY2024, which was up 28.29% from $216.4 million recorded in FY2023.
  • In the past 5 years, Legend Biotech's Total Current Liabilities ranged from a high of $297.8 million in FY2022 and a low of $115.6 million during FY2020.
  • In the last 3 years, Legend Biotech's Total Current Liabilities had a median value of $277.6 million in 2024 and averaged $264.0 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 98.33% in 2021, then fell by 27.32% in 2023.
  • Over the past 5 years, Legend Biotech's Total Current Liabilities (Yearly) stood at $115.6 million in 2020, then spiked by 98.33% to $229.2 million in 2021, then climbed by 29.92% to $297.8 million in 2022, then dropped by 27.32% to $216.4 million in 2023, then grew by 28.29% to $277.6 million in 2024.